Primary biliary cholangitis

Last updated
Primary biliary cholangitis
Other namesPrimary biliary cirrhosis
Primary biliary cirrhosis intermed mag much cropping.jpg
Micrograph of PBC showing bile duct inflammation and injury, H&E stain
Specialty Gastroenterology, Hepatology
Symptoms Cholestasis, pruritus, fatigue
Complications Cirrhosis, hepatic failure, portal hypertension
Usual onsetUsually middle-aged women
CausesAutoimmune
Risk factors Female sex
Diagnostic method Anti-mitochondrial antibodies,
Liver biopsy
Differential diagnosis Autoimmune hepatitis
Treatment Ursodeoxycholic acid, obeticholic acid, cholestyramine
Frequency1 in 3,000–4,000 people

Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. [1] [2] [3] It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. Further slow damage to the liver tissue can lead to scarring, fibrosis, and eventually cirrhosis.

Contents

Common symptoms are tiredness, itching, and in more advanced cases, jaundice. In early cases, the only changes may be those seen in blood tests. [4]

PBC is a relatively rare disease, affecting up to one in 3,000–4,000 people. [5] [6] As with many other autoimmune diseases, it is much more common in women, [7] with a sex ratio of at least 9:1 female to male. [1] The reasons for this disparity are unclear, but may involve the expression of sex hormones such as estrogen, which impact immune system response. [7]

The condition has been recognised since at least 1851, and was named "primary biliary cirrhosis" in 1949. [8] Because cirrhosis is a feature only of advanced disease, a change of its name to "primary biliary cholangitis" was proposed by patient advocacy groups in 2014. [9] [10]

Signs and symptoms

People with PBC experience fatigue (80%); this is a nonspecific symptom and can be debilitating, with a huge impact on quality of life. Its pathogenesis is still unknown, and is quite challenging to explore its specificity and to treat. Comorbidities that could contribute to or worsen fatigue, such as depression, hypothyroidism, anaemia, obesity, or medication side effects, should be promptly identified and treated. Dry skin and dry eyes are also common. Itching (pruritus) occurs in 20–70% of cases, [4] and can develop at any stage of the disease. Textbooks tend to describe itching in the feet and hands, but patients may also experience itching of the scalp, face, back, or other areas. The itching is typically mild-to-moderate in intensity. It may manifest as a tingling, crawling or burning sensation, and can develop even with normal liver function tests. It does not correlate with progression of liver disease, and may even improve or disappear as the disease advances. Given the impact on quality of life and night sleep, pruritus is also correlated with fatigue. It can rarely be severe, non-responsive to medical therapy, and requiring liver transplant. Pruritus is characteristically intermittent, worse at night, and improves during summer. People with more severe PBC may have jaundice (yellowing of the eyes and skin). [4] PBC impairs bone density and the risk of fracture increases. [4] Xanthelasma (skin lesions around the eyes) or other xanthoma may be present as a result of increased cholesterol levels. [11]

PBC can eventually progress to cirrhosis of the liver. This, in turn, may lead to a number of symptoms or complications, including:

People with PBC may also sometimes have the findings of an associated extrahepatic autoimmune disorder such as thyroid disease or rheumatoid arthritis or Sjögren's syndrome (in up to 80% of cases). [11] [12]

Causes

PBC has an immunological basis, and is classified as an autoimmune disorder. It results from a slow, progressive destruction of the small bile ducts of the liver, with the intralobular ducts and the canals of Hering (intrahepatic ductules) being affected early in the disease.

Most people with PBC (more than 90%) have antimitochondrial antibodies (AMAs) against pyruvate dehydrogenase complex (PDC-E2), an enzyme complex found in the mitochondria. People who are negative for AMAs are usually found to be positive when more sensitive methods of detection are used. [13]

People with PBC may also have been diagnosed with another autoimmune disease, such as a rheumatological, endocrinological, gastrointestinal, pulmonary, or dermatological condition, suggesting shared genetic and immune abnormalities. [12] Common associations include Sjögren's syndrome, systemic sclerosis, rheumatoid arthritis, lupus, hypothyroidism, and coeliac disease. [14] [15]

A genetic predisposition to disease has been thought to be important for some time. Evidence for this includes cases of PBC in family members, identical twins both having the condition (concordance), and clustering of PBC with other autoimmune diseases. In 2009, a Canadian-led group of investigators reported in the New England Journal of Medicine results from the first PBC genome-wide association study. [16] [17] This research revealed parts of the IL12 signaling cascade, particularly IL12A and IL12RB2 polymorphisms, to be important in the aetiology of the disease in addition to the HLA region. In 2012, two independent PBC association studies increased the total number of genomic regions associated to 26, implicating many genes involved in cytokine regulation such as TYK2 , SH2B3 and TNFSF11 . [18] [19]

A study of over 2,000 patients identified a gene, POGLUT1 , that appeared to be associated with this condition. [20] Earlier studies have also suggested that this gene may be involved. The implicated protein is an endoplasmic reticulum O-glucosyltransferase.

An environmental Gram-negative Alphaproteobacterium — Novosphingobium aromaticivorans [21] has been associated with this disease, with several reports suggesting an aetiological role for this organism. [22] [23] [24] The mechanism appears to be a cross-reaction between the proteins of the bacterium and the mitochondrial proteins of the liver cells. The gene encoding CD101 may also play a role in host susceptibility to this disease. [25]

A failure of immune tolerance against the mitochondrial pyruvate dehydrogenase complex (PDC-E2) is a primary cause, with shedding of the antigen into apoptotic bodies or "apotopes" leading to the anatomic localization. [26] Such autoreactivity may also be the case with other proteins, including the gp210 and p62 nuclear pore proteins. Gp210 has increased expression in the bile duct of anti-gp210 positive patients, and these proteins may be associated with prognosis. [27]

Diagnosis

Most patients are currently diagnosed when asymptomatic, having been referred to the hepatologist for abnormal liver function tests (mostly raised GGT or alkaline phosphatase) performed for annual screening blood tests. Other frequent scenarios include screening of patients with nonliver autoimmune diseases, e.g. rheumatoid arthritis, or investigation of elevated cholesterol, evaluation of itch or unresolved cholestasis post partum. Diagnosing PBC is generally straightforward. The basis for a definite diagnosis are:

Antinuclear antibody measurements are not diagnostic for PBC because they are not specific, but may have a role in prognosis.
Anti-glycoprotein-210 antibodies, and to a lesser degree anti-p62 antibodies, correlate with the disease's progression toward end-stage liver failure. Anti-gp210 antibodies are found in 47% of PBC patients. [28] [29]
Anti-centromere antibodies often correlate with developing portal hypertension. [30]
Anti-np62 [31] and anti-sp100 are also found in association with PBC.

Given the high specificity of serological markers, liver biopsy is not necessary for the diagnosis of PBC; however, it is still necessary when PBC-specific antibodies are absent, or when co-existent autoimmune hepatitis or nonalcoholic steatohepatitis is suspected. Liver biopsy can be useful to stage the disease for fibrosis and ductopenia. Finally, it may also be appropriate in the presence of other extrahepatic comorbidities.

Liver biopsy

On microscopic examination of liver biopsy specimens, PBC is characterized by chronic, nonsuppurative inflammation, which surrounds and destroys interlobular and septal bile ducts. These histopathologic findings in primary biliary cholangitis include: [32]

The Ludwig and Scheuer scoring systems have historically been used to stratify four stages of PBC, with stage 4 indicating the presence of cirrhosis. In the new system of Nakanuma, the stage of disease is based on fibrosis, bile duct loss, and features of cholestasis, i.e. deposition of orcein-positive granules, whereas the grade of necroinflammatory activity is based on cholangitis and interface hepatitis. The accumulation of orcein-positive granules occurs evenly across the PBC liver, which means that staging using the Nakanuma system is more reliable regarding sampling variability.

Liver biopsy for the diagnosis and staging of PBC lost favour after the evidence of a patchy distribution of the duct lesions and fibrosis across the organ. The widespread availability of noninvasive measures of fibrosis means that liver biopsy for staging of PBC is somewhat obsolete. Liver biopsy does, however, remain useful in certain settings. The main indications are to confirm the diagnosis of PBC when PBC-specific antibodies are absent and confirm a diagnosis of PBC with AIH features (i.e. overlap PBC-AIH). Liver biopsy is also useful to assess the relative contribution of each liver injury when a comorbid liver disease is present, such as non-alcoholic steatohepatitis. In patients with inadequate response to UDCA, liver biopsy may provide the explanation and could undoubtedly inform risk stratification. For example, it may identify a previously unsuspected variant syndrome, steatohepatitis, or interface hepatitis of moderate or greater severity. It is also useful in AMA and ANA-specific antibody negative cholestatic patients to indicate an alternative process, e.g. sarcoidosis, small duct PSC, adult idiopathic ductopenia.

Histopathology stages (by Ludwig and Scheuer systems)

Treatment

Cholestasis

Medical therapy of PBC targets disease progression and symptom control. The first-line treatment for PBC is ursodeoxycholic acid (UDCA). [33] [34] UDCA has been the only drug available for two decades and more recently obeticholic acid (OCA), a semi-synthetic hydrophobic bile acid analogue, has been licensed in patients failing UDCA response or intolerant to UDCA. Several other agents have been studied, including immunosuppressants, but robust evidence of benefit is lacking. [11] [35] [36]

UDCA improves liver enzyme levels, slows down histological progression, and improves liver transplant-free survival. [37] [11] UDCA also reduces the need for liver transplantation. [33] UDCA should be taken at a dose of 13 to 15 mg per kg of body weight per day, [34] usually in two divided doses each day. [33] Liver chemistries usually improve within a few weeks of starting UDCA, and 90% of any benefit is observed after 6–9 months of therapy. [33] Liver chemistries should be re-evaluated after 1 year of treatment. [33] UDCA is usually continued lifelong. [34] Up to 40% of people do not respond to treatment with UDCA. [33] Patients with PBC who have an inadequate response to UDCA or those few (less than 3%) who are intolerant to UDCA are candidates for second-line therapies.

Obeticholic acid (OCA) is FDA-approved for the treatment of PBC in individuals intolerant or unresponsive to UDCA. [33] OCA is a farnesoid X receptor agonist, and results in increased bile flow (choleresis). OCA is started at 5 mg daily, and liver chemistries should be rechecked after 3 months of treatment. If the liver chemistries remain elevated, then the dose of OCA may be increased to 10 mg per day. The most common side effect of OCA is pruritus.

Fibric acid derivatives, or fibrates, are agonists of the peroxisome proliferator activator receptor (PPAR), a nuclear receptor involved in several metabolic pathways. While fibrates are approved for the treatment of hypertriglyceridemia, they exert anticholestatic effects and have been studied for the treatment of PBC. [33] Among the fibrates, bezafibrate and fenofibrate, PPAR-alpha selective agonists, have been extensively studied as therapeutic agents because of their potential ability to decrease bile acid synthesis and bile acid-related hepatic inflammation. A randomized, controlled trial in 2018 showed its efficacy in patients with inadequate response to UDCA. While fibrates can be considered as off-label treatment for PBC that does not respond to UDCA, they should not be used in decompensated cirrhosis. [33]

Several additional medications have been investigated as potential treatments for PBC, and found to be ineffective as single agents (monotherapy), including: chlorambucil, colchicine, cyclosporine, corticosteroids, azathioprine, malotilate, methotrexate, mycophenolate mofetil, penicillamine, and thalidomide. [33] Budesonide may be used as an off-label treatment for PBC, although its efficacy is controversial. [33] Seladelpar, a PPAR-delta receptor agonist, is being studied for treatment of PBC. [38] [39]

Itching

Pruritus is a common symptom in people with PBC. First-line treatment of pruritus consists of anion-exchange resins, such as cholestyramine, colestipol, or colesevalam. [33] These anion-exchange resins are nonabsorbed, highly positively charged substances that bind bile acids, which are negatively charged anions. [33] Anion-exchange resins relieve itching caused by excess bile acids in circulation by binding bile acids in the gut and facilitating elimination. Bloating or constipation may occur with anion-exchange resins. [33] Cholestyramine may affect absorption of UDCA; if cholestyramine is necessary, it should be taken at least 60 minutes before or 4 hours after UDCA is taken. [33]

Treatment options for pruritus that does not improve with anion-exchange resins include: rifampicin, naltrexone, or sertraline. [33] Rifampicin may rarely cause drug induced liver injury and should be avoided if serum bilirubin is elevated (greater than 2.5 mg/dL). Liver enzymes should be monitored after starting rifampin. [34] Rifampicin induces enzymes, resulting in numerous potential drug-drug interactions. [33] Opioid antagonists may cause a self-limited opioid withdrawal like reaction, with abdominal pain, elevated blood pressure, tachycardia, goose bumps, nightmares, and depersonalization. [33] To avoid such reactions, the dose should start low and gradually be increased. [33]

Other therapies

Prognosis

The introduction of UDCA has dramatically changed the pattern and the course of the disease. Numerous trials and observational studies have demonstrated its efficacy on liver biochemistry, histological progression, and transplant-free survival. [44]

Among the UDCA-treated patients, the degree of the liver biochemistry improvement, i.e. the UDCA-response, identifies patients with different long-term prognosis. In the absence of cirrhosis, people who experience an improvement of liver enzymes to the normal range on treatment with UDCA have excellent survival, which may be similar to the general population. [45] Survival is significantly reduced though, in those with abnormal liver biochemistry on treatment.

The two most important parameters in evaluating response to UDCA are alkaline phosphatase and total bilirubin. Qualitative and quantitative definitions of UDCA-response have been developed, based on changes of bilirubin, transaminases and ALP, after a period of 6 to 24 months of treatment with UDCA at 13–15 mg/kg/day. [46]

Patients at diagnosis can be risk-stratified based on the probability of UDCA-response. This is relevant to identify patients who would be eligible for second-line therapies before waiting for the treatment failure under UDCA, with potential impact on disease course. [47]

Hepatocellular carcinoma (HCC) is infrequent in PBC. Recent large-scale cohort studies highlighted that the lack of UDCA-response after 12 months of therapy and male sex are associated with increased future risk of developing HCC in PBC.

After liver transplant, the recurrence of disease may be as high as 18% at five years, and up to 30% at 10 years. No consensus exists on risk factors for recurrence of the disease. [48]

Epidemiology

Epidemiologic studies report heterogeneous incidence rates of 0.33 to 5.8 per 100,000 inhabitants per year, and prevalence rates of 1.9 to 40.2 per 100,000 inhabitants. Such figures, in particular the prevalence, have shown some increase in the last decades. Improvement of diagnostic tools, increasing disease awareness, and digitised patient registration with facilitation of case-findings, along with improved survival, likely contributed to the rising prevalence rates. The disease has been described worldwide, though North America and Northern Europe have shown the highest incidence and prevalence rates. Whether a true variation in disease prevalence exists among populations of different geographical areas and of different ethnicity or if this is a consequence of a difference in study quality is unknown. [5] [6] PBC is more common in women, with a female:male ratio of at least 9:1. The peak incidence of PBC is in the fifth decade of life. In some areas of the US and UK, the prevalence is estimated to be as high as one in 4,000. This is much more common than in South America or Africa, which may be due to better recognition in the US and UK. [5] [6] First-degree relatives may have as much as a 500 times increase in prevalence, but if this risk is greater in the same-generation relatives or the one that follows is debated.

PBC is considered a prime example of the female preponderance in autoimmunity with a female to male ratio of up to 9:1, confirmed by large cohort studies, although some recent data, using administrative registries, suggest an increasing male prevalence. Major defects of sex chromosomes, i.e. enhanced monosomy X in female patients and an enhanced Y chromosome loss in male patients, have been described and might well explain the greater female predisposition to develop PBC. [49]

An association of a greater incidence of PBC at latitudes more distant from the Equator is similar to the pattern seen in multiple sclerosis. [50]

Typical disease onset is between 30 and 60 years, though cases have been reported of patients diagnosed at the ages of 15 and 93. Prevalence of PBC in women over the age of 45 years could exceed one in an estimated 800 individuals.

History

The first report of the disease dates back 1851 by Addison and Gull, who described a clinical picture of progressive jaundice in the absence of mechanical obstruction of the large bile ducts. Ahrens et al. in 1950 published the first detailed description of 17 patients with this condition, and coined the term "primary biliary cirrhosis". In 1959, Dame Sheila Sherlock reported a further series of PBC patients and recognised that the disease could be diagnosed in a precirrhotic stage and proposed the term "chronic intrahepatic cholestasis" as more appropriate description of this disease, but this nomenclature failed to gain acceptance, and the term "primary biliary cirrhosis" lasted for decades. In 2014, to correct the inaccuracy and remove the social stigmata of cirrhosis, as well as all the misunderstanding, disadvantages, and discrimination emanating from this misnomer in daily life for patients, international liver associations agreed to rename the disease "primary biliary cholangitis", as it is now known. [51] [8] [52] [53]

Society and culture

Support groups

PBC Foundation

The PBC Foundation is a UK-based international charity offering support and information to people with PBC and their families and friends. [54] It campaigns for increasing recognition of the disorder, improved diagnosis, and treatments, and estimates over 8,000 people are undiagnosed in the UK. [55] [56] The Foundation has supported research into PBC including the development of the PBC-40 quality of life measure published in 2004 [57] and helped establish the PBC Genetics Study. [18] [58] It was founded by Collette Thain in 1996, after she was diagnosed with the condition. [55] Thain was awarded an MBE Order of the British Empire in 2004 for her work with the Foundation. [59] The PBC Foundation helped initiate the name change campaign in 2014. [9] [10] [60]

PBCers Organization

The PBCers Organization is a US-based nonprofit patient support group that was founded by Linie Moore in 1996; it advocates for greater awareness of the disease and new treatments. [61] It supported the name change initiative. [10]

Related Research Articles

<span class="mw-page-title-main">Gallstone</span> Disease where stones form in the gallbladder

A gallstone is a stone formed within the gallbladder from precipitated bile components. The term cholelithiasis may refer to the presence of gallstones or to any disease caused by gallstones, and choledocholithiasis refers to the presence of migrated gallstones within bile ducts.

<span class="mw-page-title-main">Caroli disease</span> Medical condition

Caroli disease is a rare inherited disorder characterized by cystic dilatation of the bile ducts within the liver. There are two patterns of Caroli disease: focal or simple Caroli disease consists of abnormally widened bile ducts affecting an isolated portion of liver. The second form is more diffuse, and when associated with portal hypertension and congenital hepatic fibrosis, is often referred to as "Caroli syndrome". The underlying differences between the two types are not well understood. Caroli disease is also associated with liver failure and polycystic kidney disease. The disease affects about one in 1,000,000 people, with more reported cases of Caroli syndrome than of Caroli disease.

<span class="mw-page-title-main">Autoimmune hepatitis</span> Chronic, autoimmune disease of the liver

Autoimmune hepatitis, formerly known as lupoid hepatitis, plasma cell hepatitis, or autoimmune chronic active hepatitis, is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells, causing the liver to be inflamed. Common initial symptoms may include fatigue, nausea, muscle aches, or weight loss or signs of acute liver inflammation including fever, jaundice, and right upper quadrant abdominal pain. Individuals with autoimmune hepatitis often have no initial symptoms and the disease may be detected by abnormal liver function tests and increased protein levels during routine bloodwork or the observation of an abnormal-looking liver during abdominal surgery.

<span class="mw-page-title-main">Biliary atresia</span> Medical condition

Biliary atresia, also known as extrahepatic ductopenia and progressive obliterative cholangiopathy, is a childhood disease of the liver in which one or more bile ducts are abnormally narrow, blocked, or absent. It can be congenital or acquired. It has an incidence of one in 10,000–15,000 live births in the United States, and a prevalence of one in 16,700 in the British Isles. Biliary atresia is most common in East Asia, with a frequency of one in 5,000.

<span class="mw-page-title-main">Primary sclerosing cholangitis</span> Medical condition

Primary sclerosing cholangitis (PSC) is a long-term progressive disease of the liver and gallbladder characterized by inflammation and scarring of the bile ducts, which normally allow bile to drain from the gallbladder. Affected individuals may have no symptoms or may experience signs and symptoms of liver disease, such as yellow discoloration of the skin and eyes, itching, and abdominal pain.

<span class="mw-page-title-main">Liver disease</span> Medical condition

Liver disease, or hepatic disease, is any of many diseases of the liver. If long-lasting it is termed chronic liver disease. Although the diseases differ in detail, liver diseases often have features in common.

<span class="mw-page-title-main">Cholangiocarcinoma</span> Bile duct adenocarcinoma

Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts. Symptoms of cholangiocarcinoma may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever. Light colored stool or dark urine may also occur. Other biliary tract cancers include gallbladder cancer and cancer of the ampulla of Vater.

<span class="mw-page-title-main">Gastrointestinal disease</span> Medical condition

Gastrointestinal diseases refer to diseases involving the gastrointestinal tract, namely the esophagus, stomach, small intestine, large intestine and rectum, and the accessory organs of digestion, the liver, gallbladder, and pancreas.

<span class="mw-page-title-main">Ursodeoxycholic acid</span> Metabolite of cholesterol

Ursodeoxycholic acid (UDCA), also known as ursodiol, is a secondary bile acid, produced in humans and most other species from metabolism by intestinal bacteria. It is synthesized in the liver in some species, and was first identified in bile of bears of genus Ursus, from which its name derived. In purified form, it has been used to treat or prevent several diseases of the liver or bile ducts.

<span class="mw-page-title-main">Cholestasis</span> Medical condition

Cholestasis is a condition where the flow of bile from the liver to the duodenum is impaired. The two basic distinctions are:

<span class="mw-page-title-main">Anti-mitochondrial antibody</span> Autoantibodies against liver mitochondria, indicating primary biliary cholangitis

Anti-mitochondrial antibodies (AMA) are autoantibodies, consisting of immunoglobulins formed against mitochondria, primarily the mitochondria in cells of the liver.

<span class="mw-page-title-main">Ascending cholangitis</span> Medical condition

Ascending cholangitis, also known as acute cholangitis or simply cholangitis, is inflammation of the bile duct, usually caused by bacteria ascending from its junction with the duodenum. It tends to occur if the bile duct is already partially obstructed by gallstones.

Anti-glycoprotein-210 antibodies are directed at gp210 and are found within primary biliary cirrhosis (PBC) patients in high frequency. AGPA recognize the cytoplasmic-oriented carboxyl terminus (tail) of the protein. While AGPA is found as a prognostic marker in only a minority of PBC patients, those that did had higher mortality and were predicted a poor outcome. In addition, patients that responded to ursodeoxycholic acid (UDCA) therapy and, therefore, had AGPA reductions failed to develop end-stage liver disease relative to untreated cohort with anti-gp210 Ab. PBC patients with potentially destructive AGPA have increased expression of Nup210 in the bile duct, a potential immune tolerance-escaping factor.

<span class="mw-page-title-main">Cirrhosis</span> Chronic disease of the liver, characterized by fibrosis

Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, and end-stage liver disease, is the impaired liver function caused by the formation of scar tissue known as fibrosis due to damage caused by liver disease. Damage to the liver leads to repair of liver tissue and subsequent formation of scar tissue. Over time, scar tissue can replace normal functioning tissue, leading to the impaired liver function of cirrhosis. The disease typically develops slowly over months or years. Early symptoms may include tiredness, weakness, loss of appetite, unexplained weight loss, nausea and vomiting, and discomfort in the right upper quadrant of the abdomen. As the disease worsens, symptoms may include itchiness, swelling in the lower legs, fluid build-up in the abdomen, jaundice, bruising easily, and the development of spider-like blood vessels in the skin. The fluid build-up in the abdomen may develop into spontaneous infections. More serious complications include hepatic encephalopathy, bleeding from dilated veins in the esophagus, stomach, or intestines, and liver cancer.

Secondary sclerosing cholangitis (SSC) is a chronic cholestatic liver disease. SSC is a sclerosing cholangitis with a known cause. Alternatively, if no cause can be identified, then primary sclerosing cholangitis is diagnosed. SSC is an aggressive and rare disease with complex and multiple causes. It is characterized by inflammation, fibrosis, destruction of the biliary tree and biliary cirrhosis. It can be treated with minor interventions such as continued antibiotic use and monitoring, or in more serious cases, laparoscopic surgery intervention, and possibly a liver transplant.

Vanishing bile duct syndrome is a loose collection of diseases which leads to the injury to hepatic bile ducts and eventual ductopenia.

<span class="mw-page-title-main">Seladelpar</span> Chemical compound

Seladelpar is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV. The drug completed a phase II trial for primary biliary cholangitis. "Seladelpar demonstrated robust, dose-dependent, clinically significant, and durable improvements in biochemical markers of cholestasis and inflammation in patients with PBC at risk of disease progression. Seladelpar appeared safe and well tolerated and was not associated with any increase in pruritus." A phase III trial in patients with PBC also found reduced pruritus and improved liver biochemistry, despite being terminated early.

<span class="mw-page-title-main">Obeticholic acid</span> Chemical compound

Obeticholic acid (OCA), sold under the brand name Ocaliva, is a semi-synthetic bile acid analogue which has the chemical structure 6α-ethyl-chenodeoxycholic acid. It is used as a medication used to treat primary biliary cholangitis. Intercept Pharmaceuticals Inc. hold the worldwide rights to develop OCA outside Japan and China, where it is licensed to Dainippon Sumitomo Pharma.

<span class="mw-page-title-main">Biliary endoscopic sphincterotomy</span> Use of endoscopy and fluoroscopy to treat and diagnose digestive issues.

Biliary endoscopic sphincterotomy is a procedure where the sphincter of Oddi and the segment of the common bile duct where it enters the duodenum are cannulated and then cut with a sphincterotome, a device that includes a wire which cuts with an electric current (electrocautery).

References

  1. 1 2 Poupon R (May 2010). "Primary biliary cirrhosis: a 2010 update". Journal of Hepatology. 52 (5): 745–758. doi: 10.1016/j.jhep.2009.11.027 . PMID   20347176.
  2. ↑ Hirschfield GM, Gershwin ME (January 2013). "The immunobiology and pathophysiology of primary biliary cirrhosis". Annual Review of Pathology. 8: 303–330. doi:10.1146/annurev-pathol-020712-164014. PMID   23347352.
  3. ↑ Dancygier H (2010). Principles and Practice of Clinical Hepatology. Springer. pp. 895–. ISBN   978-3-642-04509-7 . Retrieved 29 June 2010.
  4. 1 2 3 4 Selmi C, Bowlus CL, Gershwin ME, Coppel RL (May 2011). "Primary biliary cirrhosis". Lancet. 377 (9777): 1600–1609. doi:10.1016/S0140-6736(10)61965-4. PMID   21529926. S2CID   2741153.
  5. 1 2 3 Boonstra K, Beuers U, Ponsioen CY (May 2012). "Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review". Journal of Hepatology. 56 (5): 1181–1188. doi: 10.1016/j.jhep.2011.10.025 . PMID   22245904.
  6. 1 2 3 James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV (August 1999). "Primary biliary cirrhosis once rare, now common in the United Kingdom?". Hepatology. 30 (2): 390–394. doi:10.1002/hep.510300213. PMID   10421645. S2CID   25248575.
  7. 1 2 Moulton, Vaishali R. (2018). "Sex Hormones in Acquired Immunity and Autoimmune Disease". Frontiers in Immunology. 9: 2279. doi: 10.3389/fimmu.2018.02279 . ISSN   1664-3224. PMC   6180207 . PMID   30337927.
  8. 1 2 Dauphinee JA, Sinclair JC (July 1949). "Primary biliary cirrhosis". Canadian Medical Association Journal. 61 (1): 1–6. PMC   1591584 . PMID   18153470.
  9. 1 2 PBC Foundation (UK). "PBC Name Change" . Retrieved 27 Jan 2017.
  10. 1 2 3 "Primary Biliary Cirrhosis Name Change Initiative" (PDF). PBCers Organization. Archived from the original (PDF) on April 19, 2015. Retrieved September 15, 2022.
  11. 1 2 3 4 5 6 7 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ (July 2009). "Primary biliary cirrhosis". Hepatology. 50 (1): 291–308. doi: 10.1002/hep.22906 . PMID   19554543. S2CID   439839. The AASLD Practice Guideline
  12. 1 2 Floreani A, Franceschet I, Cazzagon N (August 2014). "Primary biliary cirrhosis: overlaps with other autoimmune disorders". Seminars in Liver Disease. 34 (3): 352–360. doi:10.1055/s-0034-1383734. hdl:11577/3143751. PMID   25057958. S2CID   21382956.
  13. 1 2 Vierling JM (February 2004). "Primary Biliary Cirrhosis and Autoimmune Cholangiopathy". Clinics in Liver Disease. 8 (1): 177–194. doi:10.1016/S1089-3261(03)00132-6. PMID   15062200.
  14. ↑ Narciso-Schiavon JL, Schiavon LL (February 2017). "To screen or not to screen? Celiac antibodies in liver diseases". World Journal of Gastroenterology (Review). 23 (5): 776–791. doi: 10.3748/wjg.v23.i5.776 . PMC   5296194 . PMID   28223722. Lock-green.svg
  15. ↑ Volta U, Rodrigo L, Granito A, Petrolini N, Muratori P, Muratori L, et al. (October 2002). "Celiac disease in autoimmune cholestatic liver disorders". The American Journal of Gastroenterology. 97 (10): 2609–2613. doi:10.1111/j.1572-0241.2002.06031.x. PMID   12385447. S2CID   17375127.
  16. ↑ Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. (June 2009). "Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants". The New England Journal of Medicine. 360 (24): 2544–2555. doi:10.1056/NEJMoa0810440. PMC   2857316 . PMID   19458352.
  17. ↑ "UK-PBC – Stratified Medicine in Primary Biliary Cholangitis (PBC; formally known as Cirrhosis)".
  18. 1 2 Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, et al. (October 2012). "Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis". Nature Genetics. 44 (10): 1137–1141. doi:10.1038/ng.2395. PMC   3459817 . PMID   22961000.
  19. ↑ Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, et al. (December 2012). "Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants". Human Molecular Genetics. 21 (23): 5209–5221. doi:10.1093/hmg/dds359. PMC   3490520 . PMID   22936693.
  20. ↑ Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, et al. (January 2019). "POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33". Scientific Reports. 9 (1): 102. Bibcode:2019NatSR...9..102H. doi:10.1038/s41598-018-36490-1. PMC   6331557 . PMID   30643196.
  21. ↑ Selmi C, Balkwill DL, Invernizzi P, Ansari AA, Coppel RL, Podda M, et al. (November 2003). "Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium". Hepatology. 38 (5): 1250–1257. doi: 10.1053/jhep.2003.50446 . PMID   14578864. S2CID   22691658.
  22. ↑ Mohammed JP, Mattner J (July 2009). "Autoimmune disease triggered by infection with alphaproteobacteria". Expert Review of Clinical Immunology. 5 (4): 369–379. doi:10.1586/ECI.09.23. PMC   2742979 . PMID   20161124.
  23. ↑ Kaplan MM (November 2004). "Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis". The American Journal of Gastroenterology. 99 (11): 2147–2149. doi:10.1111/j.1572-0241.2004.41121.x. PMID   15554995. S2CID   19177405.
  24. ↑ Selmi C, Gershwin ME (July 2004). "Bacteria and human autoimmunity: the case of primary biliary cirrhosis". Current Opinion in Rheumatology. 16 (4): 406–410. doi:10.1097/01.bor.0000130538.76808.c2. PMID   15201604. S2CID   23532625.
  25. ↑ Mohammed JP, Fusakio ME, Rainbow DB, Moule C, Fraser HI, Clark J, et al. (July 2011). "Identification of Cd101 as a susceptibility gene for Novosphingobium aromaticivorans-induced liver autoimmunity". Journal of Immunology. 187 (1): 337–349. doi:10.4049/jimmunol.1003525. PMC   3134939 . PMID   21613619.
  26. ↑ Lleo A, Selmi C, Invernizzi P, Podda M, Coppel RL, Mackay IR, et al. (March 2009). "Apotopes and the biliary specificity of primary biliary cirrhosis". Hepatology. 49 (3): 871–879. doi:10.1002/hep.22736. PMC   2665925 . PMID   19185000.
  27. ↑ Nakamura M, Takii Y, Ito M, Komori A, Yokoyama T, Shimizu-Yoshida Y, et al. (March 2006). "Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis". Journal of Autoimmunity. 26 (2): 138–145. doi:10.1016/j.jaut.2005.10.007. PMID   16337775.
  28. ↑ Nickowitz RE, Worman HJ (December 1993). "Autoantibodies From Patients With Primary Biliary Cirrhosis Recognize a Restricted Region Within the Cytoplasmic Tail of Nuclear Pore Membrane Glycoprotein Gp210". The Journal of Experimental Medicine. 178 (6): 2237–2242. doi:10.1084/jem.178.6.2237. PMC   2191303 . PMID   7504063.
  29. ↑ Bauer A, Habior A (2007). "Measurement of gp210 autoantibodies in sera of patients with primary biliary cirrhosis". Journal of Clinical Laboratory Analysis. 21 (4): 227–231. doi:10.1002/jcla.20170. PMC   6648998 . PMID   17621358.
  30. ↑ Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. (January 2007). "Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis". Hepatology. 45 (1): 118–127. doi: 10.1002/hep.21472 . PMID   17187436. S2CID   19225707.
  31. ↑ Nesher G, Margalit R, Ashkenazi YJ (April 2001). "Anti-nuclear envelope antibodies: Clinical associations". Seminars in Arthritis and Rheumatism. 30 (5): 313–320. doi:10.1053/sarh.2001.20266. PMID   11303304.
  32. ↑ Nakanuma Y, Tsuneyama K, Sasaki M, Harada K (August 2000). "Destruction of bile ducts in primary biliary cirrhosis". Baillière's Best Practice & Research. Clinical Gastroenterology. 14 (4): 549–570. doi:10.1053/bega.2000.0103. PMID   10976014.
  33. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M (January 2019). "Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases". Hepatology. 69 (1): 394–419. doi: 10.1002/hep.30145 . PMID   30070375.
  34. 1 2 3 4 Hirschfield, Gideon M.; Beuers, Ulrich; Corpechot, Christophe; Invernizzi, Pietro; Jones, David; Marzioni, Marco; Schramm, Christoph (July 2017). "EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis" (PDF). Journal of Hepatology. 67 (1): 145–172. doi:10.1016/j.jhep.2017.03.022. PMID   28427765.
  35. ↑ Levy C, Lindor KD (April 2003). "Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis". Current Treatment Options in Gastroenterology. 6 (2): 93–103. doi:10.1007/s11938-003-0010-0. PMID   12628068. S2CID   37469838.
  36. ↑ Oo YH, Neuberger J (2004). "Options for treatment of primary biliary cirrhosis". Drugs. 64 (20): 2261–2271. doi:10.2165/00003495-200464200-00001. PMID   15456326. S2CID   1288509.
  37. ↑ Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C (December 2012). "Ursodeoxycholic acid for primary biliary cirrhosis". The Cochrane Database of Systematic Reviews. 12 (12): CD000551. doi:10.1002/14651858.CD000551.pub3. PMC   7045744 . PMID   23235576.
  38. ↑ Hirschfield, Gideon M.; Shiffman, Mitchell L.; Gulamhusein, Aliya; Kowdley, Kris V.; Vierling, John M.; Levy, Cynthia; Kremer, Andreas E.; Zigmond, Ehud; Andreone, Pietro; Gordon, Stuart C.; Bowlus, Christopher L.; Lawitz, Eric J.; Aspinall, Richard J.; Pratt, Daniel S.; Raikhelson, Karina; Gonzalez-Huezo, Maria S.; Heneghan, Michael A.; Jeong, Sook-Hyang; Ladrón de Guevara, Alma L.; Mayo, Marlyn J.; Dalekos, George N.; Drenth, Joost P.H.; Janczewska, Ewa; Leggett, Barbara A.; Nevens, Frederik; Vargas, Victor; Zuckerman, Eli; Corpechot, Christophe; Fassio, Eduardo; Hinrichsen, Holger; Invernizzi, Pietro; Trivedi, Palak J.; Forman, Lisa; Jones, David E.J.; Ryder, Stephen D.; Swain, Mark G.; Steinberg, Alexandra; Boudes, Pol F.; Choi, Yun-Jung; McWherter, Charles A. (6 April 2023). "Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study". Hepatology. 78 (2): 397–415. doi:10.1097/HEP.0000000000000395. hdl: 11380/1319587 .
  39. ↑ Hasegawa, Sho; Yoneda, Masato; Kurita, Yusuke; Nogami, Asako; Honda, Yasushi; Hosono, Kunihiro; Nakajima, Atsushi (1 July 2021). "Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents". Drugs. 81 (10): 1181–1192. doi: 10.1007/s40265-021-01545-7 . ISSN   1179-1950. PMC   8282588 .
  40. ↑ Bacon BR, O'Grady JG (2006). Comprehensive Clinical Hepatology. Elsevier Health Sciences. pp. 283–. ISBN   978-0-323-03675-7 . Retrieved 29 June 2010.
  41. ↑ Collier JD, Ninkovic M, Compston JE (February 2002). "Guidelines on the management of osteoporosis associated with chronic liver disease". Gut. 50 (Suppl 1): i1–i9. doi:10.1136/gut.50.suppl_1.i1. PMC   1867644 . PMID   11788576.
  42. ↑ Clavien PA, Killenberg PG (2006). Medical Care of the Liver Transplant Patient: Total Pre-, Intra- and Post-Operative Management. Wiley-Blackwell. p. 155. ISBN   978-1-4051-3032-5.
  43. ↑ Kaneko J, Sugawara Y, Tamura S, Aoki T, Hasegawa K, Yamashiki N, Kokudo N (January 2012). "Long-term outcome of living donor liver transplantation for primary biliary cirrhosis". Transplant International. 25 (1): 7–12. doi: 10.1111/j.1432-2277.2011.01336.x . PMID   21923804. S2CID   19872625.
  44. ↑ Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. (March 2013). "Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid". Gastroenterology. 144 (3): 560–569. doi: 10.1053/j.gastro.2012.12.005 . PMID   23246637.
  45. ↑ Lleo A, Wang GQ, Gershwin ME, Hirschfield GM (December 2020). "Primary biliary cholangitis". Lancet. 396 (10266): 1915–1926. doi:10.1016/S0140-6736(20)31607-X. PMID   33308474. S2CID   228086916.
  46. ↑ Cristoferi L, Nardi A, Ronca V, Invernizzi P, Mells G, Carbone M (December 2018). "Prognostic models in primary biliary cholangitis". Journal of Autoimmunity. 95 (1): 171–178. doi:10.1016/j.jaut.2018.10.024. PMID   30420264. S2CID   53292973.
  47. ↑ Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, et al. (September 2018). "Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score". The Lancet. Gastroenterology & Hepatology. 3 (9): 626–634. doi:10.1016/S2468-1253(18)30163-8. PMC   6962055 . PMID   30017646.
  48. ↑ Clavien & Killenberg 2006 , p. 429
  49. ↑ Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Grati FR, Simoni G, et al. (February 2004). "Frequency of monosomy X in women with primary biliary cirrhosis". Lancet. 363 (9408): 533–535. doi:10.1016/S0140-6736(04)15541-4. PMID   14975617. S2CID   5309.
  50. ↑ Webb GJ, Ryan RP, Marshall TP, Hirschfield GM (December 2021). "The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude". Clinical Gastroenterology and Hepatology. 19 (12): 2587–2596. doi: 10.1016/j.cgh.2021.01.029 . PMC   8661127 . PMID   33493696.
  51. ↑ Reuben A (January 2003). "The serology of the Addison-Gull syndrome". Hepatology. 37 (1): 225–228. doi: 10.1002/hep.510370134 . PMID   12500211. S2CID   42297264.
  52. ↑ Walker JG, Doniach D, Roitt IM, Sherlock S (April 1965). "Serological Tests in Diagnosis of Primary Biliary Cirrhosis". Lancet. 1 (7390): 827–831. doi:10.1016/s0140-6736(65)91372-3. PMID   14263538.
  53. ↑ Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, James OF (1986). "Positive Antimitochondrial Antibody but Normal Alkaline Phosphatase: Is this Primary Biliary Cirrhosis?". Hepatology. 6 (6): 1279–1284. doi:10.1002/hep.1840060609. PMID   3793004. S2CID   13626588.
  54. ↑ Association of Medical Research Charities. "The PBC Foundation". Archived from the original on 4 March 2016. Retrieved 12 July 2015.
  55. 1 2 Staff (3 January 2008). "Dealing with a silent killer". The Scotsman.
  56. ↑ Thain C (2015). "Primary Biliary Cirrhosis: Getting a Diagnosis". At Home Magazine. Archived from the original (online) on 13 July 2015. Retrieved 28 July 2015.
  57. ↑ Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OF, Jones DE (November 2005). "Development, Validation, and Evaluation of the PBC-40, a Disease Specific Health-Related Quality of Life Measure for Primary Biliary Cirrhosis". Gut. 54 (11): 1622–1629. doi:10.1136/gut.2005.065862. PMC   1774759 . PMID   15961522.
  58. ↑ Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, et al. (March 2011). "Genome-Wide Association study Identifies 12 New Susceptibility Loci for Primary Biliary Cirrhosis". Nature Genetics. 43 (4): 329–332. doi:10.1038/ng.789. PMC   3071550 . PMID   21399635.
  59. ↑ Gordon B (31 December 2003). "A royal seal of approval". The Scotsman.
  60. ↑ PBC Foundation. "EASL Name Change Presentation". Archived from the original on 9 July 2015. Retrieved 8 July 2015.
  61. ↑ Kim M (2015-01-18). "New hope for PBC liver disease". ABC30 Action news. Retrieved 4 August 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.